AstraZeneca Acquires Omniose for Bacterial Vaccine Platform

Omniose builds the attachment step into the cell producing its vaccine components. That approach to molecular assembly is now part of AstraZeneca, which acquired the St. Louis biotechnology company after an exclusive research collaboration. Omniose disclosed the completed acquisition on November 10, 2026, saying it had become a wholly owned subsidiary within AstraZeneca's Infectious Disease Unit.

The deal brings a preclinical bacterial-vaccine platform and its scientific expertise into a partner already familiar with the work. Financial terms were not disclosed, and the announcement provides no clinical results or launch schedule. Its strategic interest lies in the connection between vaccine design and the practical work of making the product, with ownership now bringing those development choices inside AstraZeneca.

How Omniose's bioconjugation platform works

A conjugate vaccine joins a bacterial polysaccharide, a chain of sugar molecules, to a carrier protein. Omniose's technology description explains why that attachment deserves attention: conventional chemical conjugation involves complex processing, and the resulting material can be difficult to reproduce and characterize. The way the components are joined therefore becomes part of the development problem, alongside the choice of bacterial target.

Omniose uses an engineered E. coli cell to produce the sugar antigen, a carrier protein and an enzyme that links the components. The company describes its approach as a way to broaden the range of bacterial sugars that can be attached through bioconjugation. A more versatile attachment method could give researchers additional design options, though the practical benefit has to be established for the vaccine being developed.

This is where the manufacturing discussion enters surprisingly early. A researcher choosing a target also needs a workable route to producing and assessing the resulting material. Omniose says its process may simplify manufacture and allow more precise molecular design; the acquisition announcement supplies no cost, yield or comparative clinical data. AstraZeneca is acquiring a way to pursue that work, with the development questions still attached to the technology.

A research partnership becomes ownership

The relationship predates the purchase by almost 3 years. In its January 5, 2024 collaboration announcement, Omniose said AstraZeneca would receive exclusive access to its bioconjugation platform for up to 3 years. The agreement concerned potential bacterial-pathogen vaccines in AstraZeneca's early pipeline, giving the partners a defined scientific relationship before the ownership decision.

That history changes how to read the acquisition announcement. AstraZeneca had already worked with the platform through an exclusive arrangement. Bringing Omniose into the Infectious Disease Unit now places the acquired technology and expertise within the buyer's organization, rather than extending the same external research relationship indefinitely.

For a biotech founder, the sequence is a useful example of how scientific collaboration can precede an exit. Work performed with a partner can give both organizations experience of the technology and the people developing it. The public record does not reveal AstraZeneca's valuation process or negotiations, so the history supports an observation about the relationship, rather than a claim about what persuaded the buyer to sign.

The scientists behind the development handoff

Omniose CEO Timothy Cooke and CSO and co-founder Christian Harding represent different parts of the development task. The company's 2022 leadership announcement describes Cooke's vaccine-industry experience and identifies Harding as the research team's leader. At the time of the acquisition, both were quoted in those same executive roles, linking the transaction to an established operating and scientific team.

Omniose's company history traces its research operations to BioGenerator Labs in St. Louis and its earlier identity as VaxNewMo. It identifies Mario Feldman and Harding as scientific founders behind the glycoconjugation discoveries and also lists Christine Szymanski as a co-founder. That background places the platform within a continuing research effort, rather than treating the acquisition as the first meaningful event in the company's life.

For AstraZeneca, Benjamin Moutier, SVP, Infectious Disease, described the platform as strengthening the company's work on vaccines against serious bacterial infections. Cooke connected the shared effort to infections complicated by antimicrobial resistance. Those statements establish the intended direction of the work, while leaving the selection and timing of future development milestones undisclosed.

What AstraZeneca can develop from here

The announced transaction is complete, and Omniose is now a subsidiary. A separate legal closing date, purchase-price breakdown and regulatory conditions were not provided in the release. The relevant operating change is the location of the platform and expertise inside AstraZeneca's infectious-disease organization, where they are intended to support preclinical vaccine programs.

For operators assessing similar technology, the acquisition illustrates how a manufacturing approach can itself become a strategic asset. The method used to assemble a vaccine influences which designs a team can pursue and how it can study the resulting material. That makes the connection between research and production part of the buyer's interest, even before a commercial product exists.

AstraZeneca now owns the platform its scientists had been working with under exclusive rights. The next development decisions will bring the choice of bacterial targets, carrier proteins and manufacturing approach into the same organization. For the Omniose team, the route toward patients continues through that combination of scientific design and the painstaking work of producing something that can advance beyond the laboratory.